|
Variables
|
Frequency (N = 602)
|
Percent (%)
|
|---|
|
IPT
|
|
Not received
|
262
|
43.2
|
|
Received
|
340
|
56.8
|
|
CPT
|
|
Not receiving
|
184
|
30.6
|
|
Receiving
|
418
|
69.4
|
|
Opportunistic infection
|
|
No OI
|
469
|
77.9
|
|
Have OI
|
133
|
22.1
|
|
WHO clinical stage
|
|
Stage I
|
55
|
9.1
|
|
Stage II
|
172
|
28.6
|
|
Stage III
|
325
|
54.0
|
|
Stage IV
|
50
|
8.3
|
|
ART regimen
|
|
1c(AZT-3TC-NVP)
|
97
|
16.1
|
|
1d(AZT-3TC-EFV)
|
26
|
4.3
|
|
1e(TDF-3TC-EFV)
|
410
|
68.1
|
|
1f(TDF-3TC-NVP)
|
69
|
11.5
|
|
Functional status
|
|
Working
|
444
|
73.8
|
|
Ambulatory
|
99
|
16.4
|
|
Bedridden
|
59
|
9.8
|
|
Adherence
|
|
Good
|
585
|
97.2
|
|
Fair
|
12
|
2.0
|
|
Poor
|
5
|
0.8
|
|
Regimen change
|
|
No
|
555
|
92.2
|
|
Yes
|
|
First line
|
36
|
6.0
|
|
Second line
|
11
|
1.8
|
|
Nutritional status (BMI)
|
|
Normal
|
347
|
57.6
|
|
Malnourished
|
255
|
42.4
|
|
CD4 cell count (cell/mm3)
|
|
≤ 200
|
360
|
43.2
|
|
> 200
|
342
|
56.8
|
- AZT zidovudine, 3TC lamivudine, NVP nevirapine, EFV efavirenz, TDF tenofovier
